CLINICAL TRIALS PROFILE FOR FLUOCINONIDE

All Clinical Trials for fluocinonide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00297011 ↗	Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis	Completed	GlaxoSmithKline	Phase 2	2004-09-01	A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00297011 ↗	Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis	Completed	University of Utah	Phase 2	2004-09-01	A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
NCT00667589 ↗	Sorafenib-induced Hand- Foot Skin Reaction Treatment	Terminated	Bayer	Phase 2	2008-06-01	The purpose of this study is to evaluate treatments for a rash caused by sorafenib.
NCT00667589 ↗	Sorafenib-induced Hand- Foot Skin Reaction Treatment	Terminated	Northwestern University	Phase 2	2008-06-01	The purpose of this study is to evaluate treatments for a rash caused by sorafenib.
NCT00819507 ↗	VANOS Cream and Skin Barrier Function	Completed	Medicis Pharmaceutical Corporation	Phase 4	2009-01-01	The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.
NCT00819507 ↗	VANOS Cream and Skin Barrier Function	Completed	Oregon Health and Science University	Phase 4	2009-01-01	The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.
NCT01049243 ↗	A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis	Completed	Medicis Pharmaceutical Corporation	Phase 4	2009-03-01	The purpose of this research study is to better understand how fluocinonide cream 0.1% (Vanos®) works when people use it to treat atopic dermatitis for just a few days.

Clinical Trial Conditions for fluocinonide

Condition Name

Condition Name for fluocinonide
Intervention	Trials
Atopic Dermatitis	3
Breast Carcinoma	1
Hand-foot Skin Reaction	1
Herpes Labialis	1

Condition MeSH

Condition MeSH for fluocinonide
Intervention	Trials
Dermatitis	3
Eczema	3
Dermatitis, Atopic	3
Lymphoma, T-Cell	1

Clinical Trial Locations for fluocinonide

Trials by Country

Trials by Country for fluocinonide
Location	Trials
United States	7
Italy	1

Trials by US State

Trials by US State for fluocinonide
Location	Trials
North Carolina	3
Oregon	2
Illinois	1
Utah	1

Clinical Trial Progress for fluocinonide

Clinical Trial Phase

Clinical Trial Phase for fluocinonide
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	4
N/A	2

Clinical Trial Status

Clinical Trial Status for fluocinonide
Clinical Trial Phase	Trials
Completed	6
Recruiting	1
Terminated	1

Clinical Trial Sponsors for fluocinonide

Sponsor Name

Sponsor Name for fluocinonide
Sponsor	Trials
Medicis Pharmaceutical Corporation	3
Wake Forest University	2
Wake Forest University Health Sciences need to be deleted	2

Sponsor Type

Sponsor Type for fluocinonide
Sponsor	Trials
Other	12
Industry	7
NIH	1